Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Immunocal is a proprietary, non-denatured, cysteine-rich whey protein isolate developed by Immunotec. It functions as a delivery system for cystine, which is the rate-limiting precursor for the intracellular synthesis of glutathione (GSH), a major antioxidant. By bolstering cellular glutathione levels, Immunocal aims to mitigate oxidative stress, support immune function, and provide neuroprotection. The supplement has been investigated in a wide range of clinical contexts, including neurodegenerative diseases (such as Alzheimer's disease and ALS), autism spectrum disorders, cystic fibrosis, and HIV/AIDS. It is also utilized as a nutritional intervention to enhance muscle strength in aging populations (sarcopenia) and to support functional recovery in cancer patients undergoing major surgery.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Immunocal.